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The need to develop internationally recognized good modelling practices has resulted 
from the increasing use of tissue dosimetry estimated using pharmacokinetic models in 
chemical risk assessments.  These practices would facilitate sharing of models and model 
evaluations and consistent applications in risk assessments.  Clear descriptions of good 
practices for 1) model development (i.e., research and analysis activities), 2) model 
characterization (i.e., methods to describe how consistent the model is with biology and 
strengths and limitations of available model and data, such as sensitivity analyses), 3) 
model documentation, and 4) model evaluation (i.e., independent review), will assist risk 
assessors, who need to decide whether and how to use the models, but also model 
developers who need to know what is expected for various purposes (e.g., research versus 
application in risk assessment).  The current status of the application of physiologically 
based pharmacokinetic (PBPK) models in risk assessments in Europe, Canada, and the 
United States were reviewed at the International Workshop on the Development of Good 
Modelling Practice (GMP) for PBPK Models in Greece on April 27 – 29, 2007.  The 
meeting participants identified follow-up steps towards the creation of descriptions of 
good modelling practices and research to improve the scientific basis of the models. 
Key Words: Good modelling practice; PBPK; risk Assessment.
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Introduction 
The increasing use of tissue dosimetry estimated using pharmacokinetic models in 
chemical risk assessments in multiple countries across the globe is producing greater 
awareness of the need to develop internationally recognized good modelling practices.  
These practices would facilitate sharing of models and model evaluations and consistent 
applications in risk assessments.  Clear descriptions of good practices for,  
1. model development (i.e., research and analysis activities),  
2. model characterization (i.e., methods to describe how consistent the model is with 
biology and the strengths and limitations of available model and data, e.g., 
sensitivity analyses),  
3. model documentation, and  
4. model evaluation (i.e., independent review),  
would assist not only risk assessors who need to decide whether and how to use the 
models, but also model developers who need to know what is expected for various 
purposes (e.g., research versus application in risk assessment) (Cobelli, C. et al. 1984; 
Portier, C. J. and C. M. Lyles 1996; Rescigno, A. and J. S. Beck 1987).   
 
For risk assessors, good modelling practice would describe a path forward when seeking 
to evaluate the potential for a pharmacokinetic model, particularly a physiologically 
based pharmacokinetic (PBPK) model, to contribute to a risk assessment.   Good 
modelling practices would only be one element, however, in a broader context that 
describes risk assessment practices ranging from limited information analyses (often 
referred to as default or screening analyses) to biological modelling of the toxicokinetics 
and toxicodynamic processes in animals and humans.  The shift from ‘default’ through 
‘data-informed’ approaches to risk assessment represents a ‘continuum’ of methods.  The 
transition begins with default approaches which involve empirical observations made 
from broad databases of information that were not group, species or chemical specific 
and where pharmacokinetics and dynamics were not explicitly addressed.  The next phase 
is ‘categorical’ and ‘species-specific’ approaches where substances and species are 
placed into categories based on their characteristics.  The categorical approach is 
followed by the IPCS scheme which uses compound-related and/or chemical specific 
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adjustment factors (CSAF) (IPCS 2005), that included chemical-specific pharmacokinetic 
or pharmacodynamic data.  When appropriate, fully data-derived, chemical specific, 
biologically based dose response risk assessment methods can be employed for chemicals 
of high concern or with high economic impacts. 
 
Descriptions of known or hypothesized modes of action (i.e., the toxicodynamic process) 
leading to the toxicity under consideration play key roles throughout much of the 
continuum of risk assessment methods.  A framework for organizing and evaluating 
evidence supporting modes of action has been described, which is applicable to all 
toxicity endpoints (Seed, J. et al. 2005; Sonich-Mullin, C. et al. 2001; US EPA 2005).  
Additional steps to evaluate whether a mode of action would occur in humans based upon 
what was known from other animal species have also been presented (Boobis, A. R. et al. 
2006; Boobis, A. R. et al. 2007; Seed, J. et al. 2005).  Application of toxicokinetic and 
toxicodynamic information in estimating values of factors accounting for interspecies 
extrapolation and human interindividual variability has been described (Gundert-Remy, 
U. and C. Sonich-Mullin 2002; IPCS 2005).  These factors may be addressed using 
appropriate data without a pharmacokinetic model or they may be replaced by application 
of PBPK models. 
 
For modellers, GMPs are important because they describe the kinds of model 
characterization and documentation that will be considered in a model evaluation process 
when a model is considered for application in risk assessment.  The initial creation of 
models, along with needed laboratory experimentation, can be a creative and 
unpredictable process that will be minimally altered by GMPs.  However, even at this 
very early stage, awareness of GMPs can be valuable, including recommendations when 
publishing models in the peer reviewed literature (Andersen, M. E. et al. 1995).  For 
example, modellers often try several alternative structures as they attempt to reconcile the 
available data and the description of the biology in the model.  These alternatives would 
not be documented to the same degree as a model proposed for use in risk assessment, 
but documenting these alternatives were considered important in supporting the model 
structure eventually selected (Barton, H. A. et al. 2007). 
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 The International Workshop on the Development of GMP for PBPK models1 was 
convened with two overarching themes: 
1. The selection and evaluation of an appropriate deterministic 2  model 
structure. 
2. Making PBPK techniques accessible to regulators and risk assessors. 
This was the first forum dedicated to review, discuss and promote best practice in 
deterministic PBPK model building and parameterization, including transparency in 
documentation with clear audit trails for model components, and to facilitate dialogue 
and understanding between PBPK practitioners and risk assessors and regulators. By 
bringing together PBPK modellers, mathematicians, statisticians, risk assessors, 
regulators and laboratory scientists, the sponsors3 of this workshop seek international 
implementation of PBPK modelling in risk assessment, which development of GMP for 
PBPK should facilitate. This paper presents the results and conclusions of the GMP 
workshop. 
 
Current Practice – Where do we stand? 
To move forward effectively in developing GMPs, it is useful to understand current 
practices in PBPK modelling and its application in risk assessment.  These applications 
are more widespread than has been commonly recognized.  The range of uses of PBPK 
models also need to be reflected in appropriate practice reflecting the stage of 
development or application for the particular model.  Efforts to develop GMP for other 
                                                 
1
 April 26 – April 28, 2007, at the Mediterranean Agronomic Institute of Chania, Crete, Greece. 
Presentations, and discussion papers are at http://www.hsl.gov.uk/news/news_pbpk.htm. Additional 
information is available at www.pbpk.org.  
2
 A “deterministic” model is the mathematical representation of the biological/chemical system (e.g., 
PBPK model and metabolic scheme) as opposed to a “non-deterministic” model which is the 
mathematical/statistical representation of the uncertainty, variability, and covariance of the data and 
parameters of the deterministic model (e.g., statistical model for measurement errors and population 
variability). 
3
 Sponsors of the International Workshop on the Development of Good Modelling Practice for PBPK 
models: The UK Health and Safety Executive (HSE), the UK Health and Safety Laboratory (HSL), Health 
Canada, The European Chemical Industry Council (CEFIC) and The European Centre for the Validation of 
Alternative Methods (ECVAM). 
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models applied in environmental regulation can also be informative in terms of their form, 
content, and processes. 
Value of PBPK models in risk assessments 
The need for change of the current risk assessment paradigm is due to an increasing 
demand from risk assessors and regulators for a higher precision of risk estimates, a 
greater understanding of uncertainty and variability (Allen, B. C. et al. 1996; Barton, H. 
A. et al. 1996; Clewell, H. J. et al. 1999; Clewell, H. J. et al. 2002; Cox, L. A., Jr. 1996; 
Delic, J. I. et al. 2000), a more justifiable means of extrapolating across species, routes, 
doses and time (Clewell III, H. J. and M. E. Andersen 1987), a more effective means of 
interpreting biological monitoring data (Georgopoulos, P. G. et al. 1994; Hays, S. M. et 
al. 2007) and a reduction in reliance on animal testing (Barratt, M. D. et al. 1995; 
Blaauboer, B. J. et al. 1999; Blaauboer, B. J. et al. 1996; DeJongh, J. et al. 1999).   
Incorporating PBPK modelling into the risk assessment process can advance all of these 
objectives. Further, the shift away from standard setting toward a more cost-benefit 
analysis approach to risk assessment should also see an increase in the utility of 
biologically based approaches in the support risk management decisions.  These topics 
were addressed in presentations by Dr. George Loizou of the Health and Safety 
Laboratory, UK in his introduction to the meeting and Dr. Bette Meek of Health Canada 
in a talk on “Physiologically based pharmacokinetic models (PBPK): the needs of risk 
assessors”. They are also the subject of many paper in the scientific literature as well as 
reviews (US EPA 2006). 
 
Dr. Meek elaborated on how hazard and dose-response assessment are being driven by 
mode of action and data informed approaches to characterise dose-response. These 
evolving developments in risk assessment form the basis for the IPCS harmonization 
frameworks that, consequently, should also facilitate the incorporation of PBPK 
modelling into this process.  The IPCS harmonization initiative for the risk assessment of 
chemicals seeks to improve methods through the pursuit of common principles and 
approaches by drawing on global expertise.  It does not seek to standardize the process 
but to increase understanding and acceptance by identifying potential areas of 
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convergence and work towards the development of analytical frameworks, guidance and 
associated training materials and the sharing of assessments to avoid duplication (Boobis, 
A. R. et al. 2006; Boobis, A. R. et al. 2007; IPCS 2005; Meek, B. et al. 2003; Meek, M. 
E. et al. 2003; Meek, M. E. and A. Renwick 2006; Meek, M. E. et al. 2001; Meek, M. E. 
et al. 2002; Sonich-Mullin, C. et al. 2001). 
Current status of implementation of PBPK models in risk 
assessments 
Dr. Ursula Gundert-Remy described use of PBPK models in the European Union (EU) 
Existing Substance Regulation (ESR) programme. Under this programme risk 
assessments are prepared by Rapporteur Member States (RMS) and reported as draft Risk 
Assessment Reports (RARs). The European Technical Committee then discusses draft 
RARs on New and Existing Substances (TC NES). Since the introduction of the ESR 
programme (1996 – 2007), 140 substances have been assessed.  Dr. Gundert-Remy 
briefly reviewed 80 of these chemicals to determine how many risk assessments included 
the application of PBPK modelling in the ‘toxicokinetics’ section of the RAR and 
whether the results of the PBPK analysis influenced the outcome. PBPK modelling was 
noted in the pharmacokinetic assessment of 8 chemicals (benzene, cyclohexane, acrylic 
acid, methylmethacrylate, vinyl acetate, 2-butoxyethanol, propylene methyl glycol and 
styrene).  A PBPK model was used and influenced the outcome of the risk assessment in 
the case of four substances, whereas for another four substances a PBPK model was used 
but did not influence the outcome. Therefore, PBPK analysis influenced the risk 
assessment of 5% of chemicals. The PBPK model for benzene was not used because the 
mode of action in rodent and human was considered different. The dose metric for acrylic 
acid was predicted to be 3 times lower in people than in rat, but was still not used. There 
was no explanation as to why the modelling results for cyclohexane and 
methylmethacrylate were not used. In the case of vinyl acetate, 2-butoxyethanol, and 
propylene methyl glycol (1-methoxypropan-2-ol) the interspecies uncertainty factor was 
reduced based upon analyses using the PBPK models.  As result of the quantification of 
the interspecies differences in glutathione depletion in lung cells, the classification of 
styrene as a category 2 carcinogen was changed to category 3. 
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Dr. Gundert-Remy was unable to discern if the application and acceptance of PBPK 
models in RARs was dependent upon access to PBPK expertise within any given RMS.  
The lack of a standardized procedure for the evaluation of a PBPK models and their 
output was the main concern that prevented application in other chemical risk 
assessments. Dr. Gundert-Remy was not aware of the approach to evaluation of the 
PBPK models used in these risk assessments. However, these examples of the use of 
PBPK modelling by RMS and acceptance by other Member State delegates indicate a 
shift in risk assessment practices. 
 
In the UK PBPK modelling has been used by the Health and Safety Executive (HSE) in a 
number of ways in support of its regulatory activities. A PBPK model for formaldehyde 
was formulated and used to support the position that formaldehyde should not be 
regarded as an established cause of leukemia in humans and should be considered 
unlikely to do so (Franks, S. J. 2005).  The validity of a biomarker of exposure for 2-
butoxyethanol was studied using a PBPK model (Franks, S. J. et al. 2006) and the 
robustness of past regulatory decisions were examined using PBPK models and Monte 
Carlo sampling (Delic, J. I. et al. 2000). 
 
In France, The French Agency for Environmental and Occupational Health Safety and 
INERIS are developing the use of PBPK modeling for setting reference values for 
reproductive toxicants (INERIS, 2007) [full reference: INERIS, 2007, Reprotoxicity of 
Ethylene Glycol Ethyl Ether (EGEE) in Humans – Development of a Dose-Response 
Relationship, Report DRC 07-83452-0079A] 
 
PBPK modelling has been used in Canada in the development of chemical specific 
adjustment factors for several chemicals including chloroform, 2-butoxyethanol, … 
(BETTE MEEK WRITE?) 
 
In the United States, PBPK models have been used in safety or risk assessments by 
several government Agencies including the Food and Drug Administration (FDA), the 
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Consumer Products Safety Commission (CPSC), the Occupational Safety and Health 
Administration (OSHA), and the U.S. Environmental Protection Agency (EPA).  As 
described in the presentation titled “Reducing uncertainty in risk assessment using PBPK 
Modelling: An example with methylene chloride” by Dr. Melvin E. Andersen of CIIT at 
The Hamner Institutes for Health Research, modelling for methylene chloride has 
involved an iterative hypothesis testing process for the pharmacokinetics and glutathione 
transferase-mediated mode of action leading to cancers in rodents. The mathematical 
model gave a quantitative form to the researcher’s conception of the biological system, 
permitting the development of a testable, quantitative hypothesis, the design of 
informative experiments and the ability to recognize inconsistencies between theory 
(model) and data.  The explicit description of model parameters also led to the ability to 
study and quantify uncertainty.  The PBPK model for methylene chloride has been 
widely applied in risk assessments by CPSC (Babich, M. A. 1998), OSHA for 
establishing the permissible exposure level including use of Bayesian statistical 
parameter estimation and characterization of uncertainty and variability (OSHA 1997), 
and EPA in the IRIS assessment for inhalation cancer risk (Dewoskin, R. S. 2007; US 
EPA 1987).  FDA raised concerns about the potential for teratogenicity of dermally 
applied all-trans retinoic acid that were addressed by PBPK modelling and evaluation of 
several potential dose metrics for the active morphogen (Clewell, H. J., 3rd et al. 1997; 
Rowland, M. et al. 2004).  The EPA has used PBPK models for several chemicals in 
addition to methylene chloride in IRIS assessment (Dewoskin, R. S. et al. 2006).  These 
include the cancer assessment for vinyl chloride and noncancer assessments for vinyl 
chloride, ethylene glycol monobutyl ether, and xylene.  PBPK models have been 
considered for, but not applied, in the IRIS assessments for acetone, chloroform, and 
methyl ethyl ketone.  IRIS assessments are ongoing for a number of other chemicals that 
propose to use PBPK models, such as that for trichloroethylene (Chiu, W. A. et al. 2006). 
 
What can we learn from other similar experiences? 
While use of quantitative modelling for toxicology, particularly for biologically based 
dose-response analyses, has been limited, modelling has been used extensively for 
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environmental fate and transport in European, Canadian, and US regulatory contexts.  In 
the US (Canada?, Europe?), risk assessments for specific contaminated sites or permitting 
of industrial facilities also rely heavily on often complex models for exposure pathways 
including food chains (US EPA 1989).  Interest in reading across chemicals to make 
predictions has also created efforts to describe some GMPs for quantitative structure 
activity relationship (QSAR) models.  These experiences provide perspectives potentially 
useful for the development of GMPs for PBPK modelling. 
Environmental Modelling- Achieving Acceptance in the Regulatory 
World 
Dr. Gerhard Goerlitz of Bayer Crop Science who had participated in the process in 
Europe described the development of good practice in environmental fate modelling.  
Environmental fate modelling was adopted as a regulatory tool in the European Union 
(EU) as a result of two major issues. The first was EU legislation in the late 1980s which, 
set a maximum pesticide residue concentration of 0.1 μg L-1 in both drinking and ground 
water and the second was the very long time, typically 3 to 4 years, required to conduct 
lysimeter4 studies. The latter problem meant that decisions on the identification of critical 
products and their uses as required by agriculture, while avoiding contamination of 
groundwater resources, could not be made rapidly. Environmental fate modelling was 
recognized as a promising approach to address these issues, but questions were raised 
concerning whether model predictions were sufficiently reliable and how the integrity of 
model calculations could be ensured. Clear divisions in attitudes emerged following 
initial discussions among environmental fate modellers, regulators, and registrants. 
Researchers used the models for the investigation of processes and systems, requiring 
flexibility and adaptability while maintaining full control of processes and algorithms in 
the models. Regulators and registrants wanted to predict exceedence or adherence to a 
regulatory limit, requiring scientific and legal certainty and preferred the use of models 
for which the code was not subject to alteration, provided complete documentation with 
clear audit trails for calculations and prevented accidental or intentional misuse. Further 
                                                 
4
 The measurement of the water percolating through soils and the determination of the materials dissolved 
in the water. 
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conflicts arose because version control and documentation of research models was 
frequently rudimentary, if it existed, no guidance on the selection of appropriate input 
parameters was available, and it was rarely properly established whether a model design 
was really suitable for regulatory purposes. These problems were a reflection of the fact 
that the typical research model was intended for use by a specialist with specific and 
intensive training, which at the time was almost totally lacking in regulatory agencies and 
in companies trying to assess the environmental behavior of plant protection products. 
The natural consequence was general confusion with different modellers arriving at 
completely different results while supposedly using the same models for the same 
problem.  
 
The first attempt to address this problem was a technical quick fix in the form of software 
packages comprising models and preconfigured scenarios with a user-friendly graphical 
interface. As a consequence, non-expert users still produced poor results increasing 
confusion further. There were two main reasons for this, (i) model processes, algorithms 
and standard parameters did not appropriately reflect substance properties and (ii) 
substance data from standard environmental fate studies were conceptually different from 
the model implementations.  This led to a proposal to apply good laboratory practice 
(GLP) for modelling because GLP was supposed to ensure that all data could be traced 
and reviewed and accidental input of incorrect data, as well as forgery, could be detected. 
Also, GLP had just been successfully been transferred from toxicology into the 
metabolism, environmental fate and residue analysis laboratories. On the other hand, 
measurements are never perfectly reproducible (especially not for living systems) 
whereas simulations are and GLP is difficult to apply to electronic data systems and 
calculations.  A solution was found in a short document entitled, “Rules for the correct 
performance and evaluation of model calculations for simulation of the environmental 
behavior of pesticides”. Later to be known as the ‘Codex’ this document was produced as 
a result of cooperation between two German regulatory agencies, a research institute and 
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the German Agrochemical Industry5. The Codex outlined general principles of GMP, not 
a detailed “cooking recipe” type of guidance. It focused on leaching models but was 
generally applicable to other simulation models.  It covered the following topics: 
• Selection of models 
• Documentation of models 
• Validation 
• Support 
• Official recognition and version control 
• Selection and treatment of input data 
• Consistency of input data and models 
• Documentation of simulations 
• Reporting 
• Interpretation 
The “Codex” created a basis for the regulatory acceptance of simulation models on the 
national scale in Germany, as well as forming a platform to address the requirements of 
the European directive 91/4146.  After, several informal meetings between modellers, 
regulators and registrants, the FOrum for the Coordination and Use of Simulation models 
(FOCUS) was created. The steering committee of FOCUS met under the auspices of the 
EU Directorate General for Health and Consumer Affairs (DG SANCO) for the first time 
in 1993 and approved 2 research area themes on groundwater and surface water models. 
FOCUS decisions are based on consensus. It has equal representation of regulators, 
researchers and industry. The remit is to offer technical support to the EU registration 
process (91/414). It has no administrative infrastructure, but DG SANCO provides funds 
for attendance at meetings for regulatory experts and researchers. The FOCUS committee 
meets approximately 4 times per year and has 2 permanent institutions: 
                                                 
5
 Federal Biological Research Centre for Agriculture and Forestry (BBA), the Federal Environmental 
Agency (UBA), the Fraunhofer Institute for Environmental Chemistry and Ecotoxicology (FhG IUCT) and 




• The FOCUS website7 provides all the reports of past FOCUS projects, as well as 
the actual versions of models which are recommended in the FOCUS reports as 
well as essential scenario data.   
• The Version Control Group is a technical group. Members are the model 
developers/supporters. Its responsibilities are the approval of new model versions, 
and the control of the website content. Generally, no formal meetings of the VC 
are held. 
 
Today the FOCUS reports have achieved a prominent position in the exposure 
assessment for the registration of plant protection products at the EU level. This is best 
reflected by the fact that in the present draft of the revision of the EU directive 91/414 on 
the authorization of plant protection products there are many instances where FOCUS 
reports are directly referred to as guidance on important decision points. Apart from that 
many member states use FOCUS outputs and adapted it as guidance in their exposure and 
risk assessments. 
QSAR dossiers 
Recent activities within the EU with regard to the development of templates for the 
various stages in the application of quantitative structure activity relationships (QSARs) 
potentially provide a blueprint for good PBPK modelling practice8. Templates for QSAR 
development, prediction and reporting have been proposed.  Each template is relevant to 
different stages of the risk assessment process.  In the development template, information 
on the training domain, internal validation, cross validation and external validation is 
stored.  In the prediction template the substance-specific prediction is stored. Finally, the 
reporting template should clearly state how the prediction should be used and applied.  








Future Directions – Where do we need to go? 
The following sections briefly summarize some of the major issues considered and 
recommendations from the workshop designed to facilitate the development of GMP for 
PBPK modelling as well as identify research priorities. 
 
A. Risk Assessors needs and their role in the process 
Two possible paradigms were proposed for the involvement of the risk assessor 
throughout the modelling process: 1) a continuous process – wherein one would try to 
include any issues that the risk assessor might have while the model is being developed 
and 2) an iterative process – that at appropriate times, would stop and evaluate model 
fitness for regulatory use.  The former process would occur when there is an 
interdisciplinary team involved in the model development and characterization (Barton et 
al., 2007), while the latter is typical for models that have already been published. 
 
Risk assessors have important roles to play in mode of action and dosimetry based risk 
assessments utilizing PBPK models.  These include helping to define the goals for using 
the model in the risk assessment (Clewell, H. J., 3rd et al. 2002; US EPA 2006) (Other 
REFs???) and participating in a transparent process that brings together appropriate 
interdisciplinary expertise to evaluate the model and its proposed risk assessment 
applications (Chiu, W. A. et al. 2007; Clark, L. H. et al. 2004).  Risk assessors play a 
pivotal role organizing the dose-response (e.g., critical studies and endpoints) and mode 
of action information that form the context for applying a dosimetry model.  Determining 
whether a PBPK model is reported to be parameterized for the chemical(s), including 
metabolites, species and life stages, exposure routes and matrices in the toxicity studies to 
be used in dose-response analysis or the human exposures relevant for the risk 
assessment can be accomplished by non-modellers.  Identifying the dose metrics relevant 
to the modes of action under consideration often requires communications among risk 
assessors, toxicologists, and modellers as does evaluation of the biology captured by the 
model.  Evaluation of the mathematical and computer implementation as well as 
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characterization of its consistency with available data and the model’s strengths and 
weaknesses for the proposed risk assessment applications will generally require involving 
people with appropriate mathematical, statistical, and computational expertise.  However, 
to ensure a transparent process, communications describing the review process and its 
conclusions need to be understandable to all parties. 
 
B. Model Development Practices 
Model standardization can facilitate intra- and inter-disciplinary communications, but 
faces the challenges of adapting to a variety of software used to create a wide range of 
model structures necessary to describe different kinetic behaviors and address varying 
model purposes. The establishment of a standard lexicon, nomenclature and glossary 
would facilitate efficient communication of models and avoid confusion in semantics that 
can hinder understanding.  There are significant benefits to the use of generic model 
structures; this would address the establishment of standard abbreviations or parameter 
nomenclature and glossary.  In addition, the need to justify selected aspects of the model 
could be eliminated, as is currently done by citing existing literature. To be truly generic, 
such a model would have to encompass a wide range of physiological compartments and 
all useful dose metrics. A standard methodology for model building rather than a fixed 
model form might be an alternative (Cobelli, C. et al. 1984). The use of a hybrid of these 
approaches, where a simple standard model was used as a starting point and refinements 
that took place during the modelling workflow would be conducted with a standardized 
model building methodology was seen as a viable compromise. In discussing the 
problems caused by model code that is specific to a particular solver package, it was 
agreed that the use of a standard representation similar to SBML or cellML9 would 
improve communication between modellers and risk assessors.  This type of 
representation gives a structured description of the conceptual model free of 
mathematical equations and confusing syntax. The provision of an intuitive graphical 
                                                 
9
 http://sbml.org ; www.cellml.org  
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interface such as MEGen10 could make such standard formats more accessible to non-
modellers by allowing rapid generation of this ‘PBPKML’ representation. 
 
C. Model Characterization 
Models that have been developed sufficiently to obtain reasonable correspondence with 
available data can be characterized in a variety of ways to demonstrate that they are 
mathematically and computationally free of errors and to characterize the behavior of the 
model in the region of parameter space that is biologically plausible and reasonably 
approximates the available data (Barton, H. A. et al. 2007; Oreskes, N. 1998) (OTHER 
REFS???).  Demonstration that a model is mathematically and computationally correctly 
implemented can involve checks implemented in the model (e.g., mass balance checks), 
rigorous manual checking of the equations and computer code, and independent recoding 
of the model in another software.  The ease of implementing these options varies with the 
particular software used.  A PBPK model code generator tool such as MEGen10 could 
play a role in both by permitting rapid recoding of models. 
 
Roles and methods of sensitivity analysis 
Sensitivity analysis is a tool for model characterization that can address a number of 
issues frequently raised concerning PBPK models.  This was the topic of a white paper 
prepared for the meeting entitled “Global sensitivity analysis and its role in model 
development” by Dr. Martin Spendiff and Dr. George Loizou of the UK Health and 
Safety Laboratory, as well as being discussed in the breakout group presentation, “Fit for 
purpose: a proposed approach to PBPK model evaluation”, given by Dr. Spendiff. 
 
Sensitivity analyses can be used through the processes of model development, 
characterization, and evaluation to address issues including the following: 
1. Characterize which parameters are well determined by available data.  




2. Iterating with experiments, evaluate the sensitivity of parameters to new data that will 
be collected.  Additional, formal, experimental design methods can also be used (Cho, 
K.-H. et al. 2003; Gueorguieva, I. et al. 2006; Nestorov, I. A. et al. 1998). 
3. For dose-response analysis predictions, evaluate the sensitivity of dose metrics 
predicted under the conditions relevant to the toxicity studies (or epidemiological studies) 
to the parameters in the model. 
4. For risk assessment, evaluate the predicted dose metrics in humans under relevant 
environmental exposure conditions to characterize their sensitivity with respect to the 
model parameters. 
 
The many sensitivity analysis methods that exist can be grouped into two categories: 
local methods that consider sensitivities close to a specific set of input parameter values, 
and global methods, which calculate the contribution of a parameter over the set of all 
possible input parameters. Currently, gaining insight into a model often involves the 
adjustment of individual model parameters and observation of the predicted changes in 
model output, either at a single time or throughout a time course. This useful practice can 
be supplemented by examining the time-dependent global sensitivities of the chosen 
dose-metric for dominant parameters. When trying to establish the contribution of a 
parameter to model predictions, local sensitivity analysis techniques are fairly rapid and 
simple to implement but can give somewhat misleading results if there are substantial 
interactions among multiple parameters.  Dr. Spendiff presented an example of global 
sensitivity analysis using Extended Fourier Amplitude Sensitivity Test (FAST). This is a 
variance-based global sensitivity method that is independent of any assumptions about 
the model structure and is effective for monotonic (exclusively increasing or decreasing 
predictions) and non-monotonic models (Campolongo, F., Saltelli, A. 1997). FAST is 
preferable over other global methods due to its computational efficiency and capability to 
consider parameter interactions as well as main effects. Because PBPK models will 
become more complex over time, for a sensitivity analysis technique to become 
‘standard’ for such models, it must be robust and ‘future-proof’. The FAST technique 
satisfies these criteria. Dr. Spendiff illustrated the process with an example of a PBPK 
model with 57 parameters and a specified dose metric, which predicted greater than 90% 
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variability across a population that was almost entirely determined by a small subset 
(<10) of the parameters. This does not mean that the PBPK model was over-specified as 
it is essential that the factors responsible for heterogeneity in output across all dose 
metrics, species and exposure scenarios are preserved. However, once the dose metric has 
been established, the techniques described can greatly reduce the effort required to 
perform a population simulation and provide estimates of human variability.   
 
D. Model Documentation 
Suggestions for documenting models in publications have been presented previously 
(Andersen, M. E. et al. 1995).  As noted there, model documentation must address a 
diverse readership.  Recommendations from this workshop were to develop a standard, 
brief model description summary for the broad risk assessment audience and more 
detailed documentation for specialists.  The summary would contain at least seven 
elements including:  
1. Introduction with problem formulation (applicability of model),  
2. Model textual description (species, routes, etc), schematic diagram, and overview 
of the information and data supporting the model structure 
3. Metabolic pathways for the chemical and overview of supporting information and 
data 
4. Relationship to mode of action including dose metric predictions and supporting 
information 
5. Distributional predictions and their implications (e.g., Monte Carlo simulation of 
human variability) 
6. Overview of uncertainty and sensitivity analyses. 
7. Source of complete information (e.g., citation) 
Recommendations for more complete model documentation need further development, 
but include the possibility that hyperlinked documents can facilitate easy access to 
supporting materials, including calculations done to convert published scientific 
information into the form utilized in the model.  This extended model documentation 
would be utilized by subject experts in the model evaluation process and would ideally be 
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publicly accessible via the internet.  The documentation would strive for transparency 
through the use of diagrams of model structure and metabolic pathways and tables of 
model state variables and parameters along with the mathematical equations and model 
code. 
 
E. Model Evaluation 
‘Best practices’ allow efficient evaluation of models through standardization, 
documentation, and transparency.  The framework for model evaluation described by 
Clark et al., (Clark, L. H. et al. 2004) provides a useful outline for activities in a model 
evaluation process that has also been extended by Chiu et al., (Chiu, W. A. et al. 2007).  
It would be valuable to further specify criteria that would assist reviewers in determining 
the strengths and limitation of a specific model.  More complete specifications are needed 
for the processes to be used to implement model evaluation.  Model evaluation needs to 
be a transparent, independent review process.  While involvement of risk assessors and 
modellers throughout the steps leading from model development to application in risk 
assessment is valuable, it can impact the perception of the model evaluation as an 
independent process.  An independent review is essential to identify and correct mistakes 
and to make judgments on the adequacy of the model and its supporting scientific 
database for purposes of implementing a model in risk assessment.  Such reviews present 
a challenge for regulatory Agencies with limited PBPK modelling expertise, so it may be 
necessary to access additional expertise.  It would also be valuable to be able to share 
model evaluations among countries, by agreeing upon a common framework and process 
even if the final decisions concerning model use might be different, for example due to 
risk assessment needs. 
 
A major challenge of model evaluation is to provide perspective on the scientific 
uncertainties (i.e., inexact or incomplete information) identified with the model and its 
supporting scientific database.  The models allow characterization of uncertainty in a way 
that default analyses cannot.  For example, a default value of 10 for interspecies 
extrapolation is commonly applied, but the uncertainty for any specific chemical with 
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regard to the toxicity it causes in animals ranges from a value close to zero (the effect 
only occurs in the animals) to a much larger value (the effect only occurs in humans).  
While the factor of 10 represents a judgment concerning the general tendency across 
many chemicals, it cannot describe the uncertainties for a specific chemical as one can 
start to estimate using biologically based modelling.  However, this creates a challenge 
for considering whether the model adequately captures the science and, thus, should be 
implemented in the risk assessment. 
 
Improving Science Supporting Models 
Efforts to use PBPK models more broadly have also resulted in a range of scientific 
issues that require additional research.  These include improving methods for using in 
vitro data in order to limit controlled animal and human studies, for model development 
by extrapolating across chemical to those with limited databases, and for better 
characterizing uncertainty and variability in PBPK models. 
In vitro to in vivo extrapolations 
During the presentation by Professor György Csanády of the GSF- Institute of 
Toxicology in Germany entitled “A physiological toxicokinetic model for inhaled 
propylene oxide in rat and human with special emphasis on the nose” he discussed the 
significant capabilities of this model given the complex nature of the toxicity and datasets 
it was addressing.  He noted the apparent inability of the model to predict in vivo rat data 
using metabolic parameters estimated from in vitro studies (Csanady, G. A. and J. G. 
Filser 2007; Faller, T. H. et al. 2001; Lee, M. S. et al. 2005; Osterman-Golkar, S. et al. 
2003).  Introduction of extrahepatic metabolism or reduction of the Michaelis-Menten KM 
constant was required, while a reduction in pulmonary ventilation rate was need at 
propylene oxide concentrations above 100 ppm likely reflecting respiratory irritant 
effects. The discussion stimulated by Professor Csanády’s presentation led to agreement 
that the issue of in vitro to in vivo extrapolation, particularly, with regards to metabolism 
requires further detailed study (Blaauboer, B. J. et al. 1999; Blaauboer, B. J. et al. 1996; 
DeJongh, J. et al. 1999).  Ideally, in vitro data should be readily usable in PBPK models 
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because it can limit the need for in vivo studies in animals or humans.  The importance of 
protein and non-specific binding and partitioning of volatile substrates, in particular, 
between the liquid and headspace phases are fundamental to improving the utility of in 
vitro systems and the use of such data in PBPK models. The EU 6th Framework Project 
“AcuteTox” is addressing many of these issues11.  Therefore, in vitro metabolism data 
currently must be ranked lower than in vivo until more detailed models of in vitro 
systems demonstrate that they are reliable surrogates.  In keeping with the theme of the 
workshop it was agreed that transparency and clear communication with regard to how in 
vitro data were generated and used in a model is vital.  
Cross chemical extrapolation 
Risk assessors are increasingly having to address prioritization and assessment for the 
large numbers of chemicals in commerce, notably the REACH12 legislation in Europe or 
the Categorization & Screening of the Domestic Substances List under the Canadian 
Environmental Protection Act of 199913.  Methods to develop initial PBPK models for 
chemicals using cross-chemical prediction methods would be valuable.  Efforts to date 
have primarily been directed at predicting tissue:blood or tissue:air partition coefficients 
(Beliveau, M. et al. 2005), though in vitro to in vivo extrapolation for metabolism and 
other aspects of pharmacokinetics is also receiving attention as noted in the previous 
section. 
Uncertainty and variability in PBPK models 
Much of the focus in the development of PBPK models has been to identify and capture 
the average behaviour of the key biological processes controlling a chemical’s 
pharmacokinetics.  These models have successfully assisted in evaluating biological 
hypotheses for mode of action (e.g., methylene chloride carcinogenesis described 
previously) as well as identifying previously unrecognized pharmacokinetic behaviours.  
The increasing application of PBPK models in risk assessment has led to a range of 
efforts to better characterize the relationship between the model and supporting data and 




 (http://ec.europa.eu/environment/chemicals/reach/reach_intro.htm ) 
13
  (http://www.ec.gc.ca/substances)  
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quantify uncertainty and variability as was described by Dr. R. Woodrow Setzer in his 
talk reporting on the International Workshop on Uncertainty and Variability in PBPK 
Models (Research Triangle Park, NC, 31 October – 2 November, 2006).  Improved 
computing power was essential to more widespread use of distributional analyses to 
characterize human variability with Monte Carlo simulation techniques and methods of 
parameter estimation ranging from optimization of selected chemical specific parameters 
(e.g., metabolic rates) to global parameter estimation using Bayesian statistical 
characterization of uncertainty and variability.  Priorities for research and implementation 
of uncertainty and variability concepts in risk assessments using PBPK models have been 
previously described (Barton et al., 2007). 
 
G. Good modelling practices for PBPK models: Developing a 
description, case studies, and training materials 
The International Programme on Chemical Safety (IPCS) steering group of the World 
Health Organization (WHO) identified PBPK modelling as an important component of 
chemical risk assessment that merits international harmonization14. The ability to review 
a PBPK model according to accepted criteria would greatly facilitate widespread 
acceptance, in particular, amongst regulators. While agreement amongst PBPK 
practitioners is paramount for the development of GMP, the guidelines must also be 
acceptable to regulators and risk assessors. Development of guidelines for GMP is best 
achieved through a cross-disciplinary exchange of experience and ideas among laboratory 
scientists, PBPK modellers, regulators and risk assessors.  This workshop will provide 
input to the ongoing IPCS PBPK working group, which is striving to develop a 
description of GMP. 
 
The adequacy of the GMP description can be evaluated using case studies.  The case 
studies would then form the basis for training materials on GMPs.  Some 
recommendations for case studies included: 





 Comparing a case with a dose metric for which data was directly available versus 
one where it was not. 
 Examples where PBPK models were accepted and used by regulatory Agencies 
and ones where they were rejected to insure appropriate documentation. 
 Comparisons of data rich chemicals with data limited chemicals including not just 
pharmacokinetic or metabolic data, but also mode of action data such as 
toxicogenomic or metabolomic data. 
 Illustrations of different risk assessment applications 
Potential chemicals to use as case studies would include those previously noted by 
participants as PBPK models considered for or applied in risk assessments in Europe, 
Canada, and the United States.  Other chemicals could include isopropanol (with acetone 
metabolite submodel) for noncancer endpoints, styrene as an example of an inaccessible 
dose metric, acrylamide as an example of great current regulatory interest with multiple 
proposed modes of action and target sites, butadiene due to the substantial animal 
modelling and uncertainty in human metabolism resulting in assessment based upon 
epidemiology. 
 
Finally, development of training materials and hiring of personnel with needed expertise 
will be essential to facilitate implementation of mode of action and dosimetry-based risk 
assessment by regulatory Agencies.  A strategy over a longer term would be to include a 
more quantitative, computationally based study of toxicology in university courses. The 
adaptation of a PBPK model generator tool such as MEGen as a teaching tool would be 
very useful in demonstrating to students how biological knowledge can be applied to 
solve real-world problems. Training materials are needed so that risk assessors and 
managers with diverse expertise can successfully interact with modellers to implement 
PBPK models in risk assessment.  Training will also be important for modellers to learn 
about newer methodologies for characterizing uncertainty and variability in PBPK 
models or implementing local and global sensitivity analyses at appropriate stages of 
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